+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Veterinary Oncology Market By Animal Type, By Therapy, By Cancer Type, By Country, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 90 Pages
  • April 2020
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5026315
The Latin America, Middle East and Africa Veterinary oncology Market is expected to witness market growth of 14.2% CAGR during the forecast period (2020-2026).

Veterinary radiation oncology continues to advance with the introduction of emerging technology, procedures, and guidelines while growing patient outcome knowledge. They do face gaps in expertise and require randomized clinical trials to evaluate true results for clinicians, prognostic factors, dose tolerances, and toxicity.

In animals, lymphoma (lymphosarcoma) is a type of cancer characterized by the proliferation of malignant lymphocytes in solid organs such as the lymph nodes, bone marrow, liver, and spleen. The disorder can also occur in the gastrointestinal tract of the body, skin, and. Close supervision of dogs receiving chemotherapy is necessary because of the high risk of recurrence and resulting problems. The same refers to dogs who have reached remission and have ceased treatment. Disease and remission/recurrence control is normally done by peripheral lymph node palpation. This detects significant changes in peripheral lymph nodes. Some of the blood testing used to detect lymphoma often provide more objectivity and provide an early warning of an animal coming out of remission.

Wide resection is a type of curative-intent surgery: the aim is to resect the tumor burdens macroscopic (the primary tumor) and microscopic (satellite cells), including biopsy tracks. This surgical dosage is recommended for treating and handling solid tumors over intralesional and partial resections. Radical resection involves the replacement of a whole compartment of the tissue. Examples include removing a whole organ for the diagnosis of appendicular osteosarcomas, such as splenectomy to remove a splenic hemangiosarcoma or amputation of legs. Radical resection is sometimes required to completely remove the primary tumor and its accompanying pseudocapsule and satellite tumor cells, based on tumor location, type, and size.

Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.

Scope of the Study

Market Segmentation:

By Animal Type
  • Canine and
  • Feline

By Therapy
  • Chemotherapy
  • Radiology
  • Surgery
  • Immunotherapy and
  • Others

By Cancer Type
  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer and
  • Others

By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled:
  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.

Unique Offerings from the Publisher:
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Veterinary Oncology Market, by Animal Type
1.4.2 LAMEA Veterinary Oncology Market, by Therapy
1.4.3 LAMEA Veterinary Oncology Market, by Cancer Type
1.4.4 LAMEA Veterinary Oncology Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, Sep - 2019, Nov) Leading Players
Chapter 4. LAMEA Veterinary Oncology Market by Animal Type
4.1 LAMEA Canine Market by Country
4.2 LAMEA Feline Market by Country
Chapter 5. LAMEA Veterinary Oncology Market by Therapy
5.1 LAMEA Chemotherapy Market by Country
5.2 LAMEA Radiology Market by Country
5.3 LAMEA Surgery Market by Country
5.4 LAMEA Immunotherapy Market by Country
5.5 LAMEA Other Therapy Market by Country
Chapter 6. LAMEA Veterinary Oncology Market by Cancer Type
6.1 LAMEA Lymphoma Market by Country
6.2 LAMEA Mast Cell Cancer Market by Country
6.3 LAMEA Mammary & Squamous Cell Cancer Market by Country
6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Veterinary Oncology Market by Country
7.1 Brazil Veterinary Oncology Market
7.1.1 Brazil Veterinary Oncology Market by Animal Type
7.1.2 Brazil Veterinary Oncology Market by Therapy
7.1.3 Brazil Veterinary Oncology Market by Cancer Type
7.2 Argentina Veterinary Oncology Market
7.2.1 Argentina Veterinary Oncology Market by Animal Type
7.2.2 Argentina Veterinary Oncology Market by Therapy
7.2.3 Argentina Veterinary Oncology Market by Cancer Type
7.3 UAE Veterinary Oncology Market
7.3.1 UAE Veterinary Oncology Market by Animal Type
7.3.2 UAE Veterinary Oncology Market by Therapy
7.3.3 UAE Veterinary Oncology Market by Cancer Type
7.4 Saudi Arabia Veterinary Oncology Market
7.4.1 Saudi Arabia Veterinary Oncology Market by Animal Type
7.4.2 Saudi Arabia Veterinary Oncology Market by Therapy
7.4.3 Saudi Arabia Veterinary Oncology Market by Cancer Type
7.5 South Africa Veterinary Oncology Market
7.5.1 South Africa Veterinary Oncology Market by Animal Type
7.5.2 South Africa Veterinary Oncology Market by Therapy
7.5.3 South Africa Veterinary Oncology Market by Cancer Type
7.6 Nigeria Veterinary Oncology Market
7.6.1 Nigeria Veterinary Oncology Market by Animal Type
7.6.2 Nigeria Veterinary Oncology Market by Therapy
7.6.3 Nigeria Veterinary Oncology Market by Cancer Type
7.7 Rest of LAMEA Veterinary Oncology Market
7.7.1 Rest of LAMEA Veterinary Oncology Market by Animal Type
7.7.2 Rest of LAMEA Veterinary Oncology Market by Therapy
7.7.3 Rest of LAMEA Veterinary Oncology Market by Cancer Type
Chapter 8. Company Profiles
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Karyopharm Therapeutics, Inc.
8.2.1 Company overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Regeneus Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expense
8.4 Elanco Animal Health, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.5 Zoetis, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Varian Medical Systems, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.6.5.2 Partnerships, Collaborations, and Agreements:
8.6.5.3 Product Launches and Product Expansions:
8.7 PetCure Oncology, LLC (Accelitech, LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.8 AB Science SA
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Research & Development Expense
8.9 Rhizen Pharmaceuticals S.A.
8.9.1 Company Overview
8.1 Nippon Zenyaku Kogyo Co., Ltd.
8.10.1 Company Overview

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.

Methodology

Loading
LOADING...